Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-04-04
2008-11-04
Lucas, Zachariah (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388220, C530S388700, C530S389100, C530S389600, C424S130100, C424S133100, C424S143100, C424S173100
Reexamination Certificate
active
07446177
ABSTRACT:
This invention provides a method of inhibiting HCV infection of a cell susceptible to HCV infection which comprises contacting the cell with an amount of a compound effective to inhibit binding of an HCV envelope glycoprotein to a DC-SIGN protein present on the surface of the cell, so as to thereby inhibit HCV infection of the cell susceptible to HCV infection. This invention provides a method of inhibiting HCV infection of a cell susceptible to HCV infection which comprises contacting the cell with an amount of a compound effective to inhibit binding of an HCV envelope glycoprotein to a DC-SIGNR protein present on the surface of the cell, so as to thereby inhibit HCV infection of the cell susceptible to HCV infection. Compounds of the present invention inhibit HCV infection of cells susceptible to HCV infection. The compounds of the present invention preferably have specificity for preventing or inhibiting infection by HCV and do not inhibit infection by other viruses, such as HIV, that may utilize DC-SIGN or DC-SIGNR for infection. Moreover the compounds of the present invention preferably do not interfere or inhibit members of the immunoglobulin superfamily, in particular, the compounds do not interfere with ICAM-2 or ICAM-3 or with ICAM-2-ilke, or ICAM-3-like molecules.
REFERENCES:
patent: 5595868 (1997-01-01), Habets et al.
patent: 5679342 (1997-10-01), Houghton et al.
patent: 6391567 (2002-05-01), Littman et al.
patent: 7022323 (2006-04-01), Olson et al.
patent: 2003/0013081 (2003-01-01), Olson et al.
patent: 2003/0134297 (2003-07-01), Olson et al.
patent: 2003/0232745 (2003-12-01), Olson et al.
patent: 1046651 (2000-10-01), None
patent: WO9208734 (1992-05-01), None
patent: WO9315210 (1993-08-01), None
patent: WO0063251 (2000-10-01), None
patent: WO0250119 (2002-01-01), None
patent: WO03000024 (2003-01-01), None
patent: WO2004058953 (2004-07-01), None
Daugherty et al., “Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins,”Nucleic Acids Research, vol. 19 No. 9, pp. 2471-2476 (May 1991).
Poljak et al., “Structure and specificity of antibody molecules,” Philosophical Transactions of the Royal Society of London, Series B: Biological Sciences, vol. 272, pp. 43-51 (Nov. 1975).
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,”Proceedings of the National Academy of Sciences, USA, vol. 79, pp. 1979-1983 (Mar. 1982).
Song et al., “Light Chain of Natural Antibody Plays a Dominant Role in Protein Antigen Binding,” Biochemical and Biophysical Research Communications, vol. 268, pp. 390-394 (2000).
Cocquerel et al., “Antivir Chem Chemother. 2007 ;18 (4):169-89 17907376 ,” Journal of General Virology, vol. 87 No. 5, pp. 1075-1084 (May 2006).
Walker et al.,“Heopatitis C virus therapies: current treatments, targets, and future perspectives,” Antiviral Chemistry & Chemotherapy, vol. 14 No. 1, pp. 1-21 (Jan. 2003).
Cormier et al., “L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus,” Proceedings of the National Academy of Sciences, vol. 101 No. 39, pp. 14067-14072 (Sep. 2004).
Lozach et al., “C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles,” Journal of Biological Chemistry, vol. 279 No. 3, pp. 32035-32045 (Jul. 2004).
Lai et al., “Expressoin of DC-SIGN and DC-SIGNR on human sinusoidal endothelium,” American Journal of Pathology, vol. 169 No. 1, pp. 200-208 (Jul. 2006).
Cardoso, Marcia da Silva et al. (1998) “Isolation And Characterization Of Human Monoclonal Antibodies Against Hepatitis C Virus Envelope Glycoproteins”J. of Medical Virologyvol. 55, pp. 28-34.
Habersetzer, Fracois et al., (1998) “Characterization Of Humlan Monoclonal Antibodies Specific To The Hepatitis C Virus Glycoprotein E2 With In Vitro Binding Neutralization Properties”Virologyvol. 249, pp. 32-41.
Hadlock, Kenneth et al. (2000) “Human Monoclonal Antibodies That Inhibit Blinding Of Hepatitis C Virus E2 Protein To CD81 And Recognize Conserved Conformational Epitopes”J. of Virologyvol. 74, pp. 10407-10416.
Harada, Shizuko, et al. (1995) “Establishment Of A Cell Line Constitutively Expressing E2 Glycoprotein Of Hepatitis C Virus And Humoral Response Of Hepatitis C Patients To The Expressed Protein”J. Of General Virologyvol. 76, pp. 1223-1231.
Lesniewski, R.et al. (1995) “Antibody To Hepatitis C Virus Second Envelope (HCV-E2) Glycoprotein: A New Marker Of HCV Infection Closely Associated With Viremia”J. of Medical Virologyvol. 45, pp. 415-422.
U.S. Appl. No. 60/300,971, filed Jun. 26, 2001, W.C. Olson et al.
Baribaud, F. et al. (2002) “The Role Of DC-SIGN And DC-SIGNR In HIV And Ebola Virus Infection: Can Potential Therapeutics Block Virus Transmission And Dissemination?”Expert Opinion on Therapeutic Targets, pp. 423-431.
Baribaud, F. et al. (2002) “Quantitative Expression And Virus Transmission Analysis Of DC-SiGN On Monocyte-Derived Dendritic Cells”J. of Virol, pp. 9135-9142.
Colmenares, M. et al. (2002) “Dendritic Cell (DC)-Specific Intercellular Adhesion Molecule 3 (ICAM-3)-Grabbing Nonintegrin (DC-SIGN, CD209), A C-Type Surface Lectin In Human DCS, Is A Receptor For Leishmania Amastigotes”J. of Biol. Chem. pp. 36766-36769.
Flint, M., (2001) “In Search Of Hepatitis C Virus Receptor(S)”Clinics in Liver Disease, pp. 873-893.
Gardner, J. (2003) “L-SIGN (CD 209L) Is A Liver-Specific Capture Receptor For Hepatitis C Virus.”Proceedings of the National Academy of Sciences, USA, pp. 4498-4503.
Halary, F. et al. (2002) “Human Cytomegalovirus Binding To DC-SIGN Is Required For Dendritic Cell Infection And Target Cell Trans-Infection”Immunity, pp. 653-654.
Lozach, P. et al. (2003) “DC-SIGN And L-SIGN Are High Affinity Binding Receptors For Hepatitis C Virus Glycoprotein E2.”J. of Biol. Chem., pp. 20358-20366.
Michalak, J.P. (1997) “Characterization Of Truncated Forms Of Hepatitis C Virus Glycoproteins”J. Gen. Virol., vol. 78, pp. 2299-2306.
Pohlmann, S. et al. (2001) “DC-SIGN And DC-SIGNR: Helping Hands For HIV”Trends in Immun. vol. 22 Issue 12, pp. 643-646.
Auffermann-Gretzinger, S., E.B. Keeffe, and S. Levy. 2001. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 97: 3171-3176.
Bain, C., A. Fatmi, F. Zoulim, J.P. Zarski, C. Trepo, and G. Inchauspe. 2001. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 120: 512-524.
Baribaud, F., S. Pohlmann, T. Sparwasser, M.T. Kimata, Y.K. Choi, et al. 2001. Functional and antigenic characterization of human, rhesus macaque, pigtailed macaque, and murine DC-SIGN. J. Virol. 75: 10281-10289.
Bashirova, A.A., T.B. Geijtenbeek, G.C. van Duijnhoven, S.J. van Vliet, J.B. Eilering, et al. 2001. A dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (dc-sign)-related protein is highly expressed on human liver sinusoidal endothelial cells and promotes HIV-1 infection. J. Exp. Med. 193: 671-678.
Carloni, G., S. Iacovacci, M. Sargiacomo, G. Ravagnan, A. Ponzetto, C. Peschle, and M. Battaglia. 1993. Susceptibility of human liver cell cultures to hepatitis C virus infection. Arch. Virol. Suppl. 8: 31-39.
Cocquerel, L., C. Wychowski, F. Minner, F. Penin, and J. Dubuisson. 2000. Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins. J. Virol. 74: 3623-3633.
Cocquerel, L., J.C. Meunier, A. Pillez, C. Wychowski, and J. Dubuisson. 1998. A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis
Maddon Paul J.
Olson William C.
Cooper & Dunham LLP
Lucas Zachariah
Progenics Pharmaceuticals Inc.
White John P.
LandOfFree
Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4036984